您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Ranibizumab(anti-VEGF)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Ranibizumab(anti-VEGF)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:347396-82-1
包装与价格:
包装价格(元)
200 μg电议
1mg电议
5mg电议
10mg电议

产品名称
RG-6321 (anti-VEGF)
产品介绍
Ranibizumab (RG-6321) (anti-VEGF) 是一种人源化的抗VEGF单克隆抗体片段,能够识别所有 VEGF-A 亚型 (VEGF110,VEGF121,以及 VEGF165)。动物模型中,Ranibizumab (anti-VEGF) 减缓视力丧失,并用于老年黄斑变性 (AMD) 的研究。
生物活性

Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize allVEGF-Aisoforms (VEGF110, VEGF121, and VEGF165)[1]. Ranibizumab (anti-VEGF) slows vision lossin vivoand is used for wet age-related macular degeneration (AMD) research[1].

体外研究
(In Vitro)

Ranibizumab (RG-6321) is a humanizedanti-VEGFmonoclonal antibody fragment (IgG antigen-binding fragment (Fab-Y0317)[2]. Ranibizumab (0.0625-0.25 mg/ml; 72 hours) results in increased necrosis and apoptosis at in rat retinal cell cultures[3].

体内研究
(In Vivo)

Studies in monkeys demonstrates that after a single intravitreal administration, Ranibizumab can distribute rapidly to the retina (6–24 h). Ranibizumab can rapidly penetrate through the retina to reach the choroid, just 1 h after intravitreal administration in rabbits[1].
In a study comparing the pharmacokinetics of 0.5 mg of intravitreal Ranibizumab with 1.25 mg of intravitreal Bevacizumab in the rabbit, the vitreous half-life of Ranibizumab is 2.88 days, shorter than the Bevacizumab half-life of 4.32 days. Peak concentrations in the aqueous humor of the treated eye at 3 days following treatment are 37.7 μg/ml for Bevacizumab and 17.9 μg/ml for Ranibizumab, respectively[1].

CAS 号

347396-82-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.